Cibinqo® (abrocitinib) – New drug approval
On January 14, 2022, Pfizer announced the FDA approval of Cibinqo (abrocitinib), for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Top